Table 2.
Lipid profile during the study period by treatment group, repeated measures and Bonferroni post hoc analysis, using last observation carried forward method for missing data
| |
|
PJ |
Placebo |
P *** for PJ vs. placebo at 12 m | ||||
|---|---|---|---|---|---|---|---|---|
| N | Mean ± SD | P for trend | N | Mean ± SD | P for trend | |||
| LDL mg/dl |
0 |
66 |
95.1 ± 31.5 |
0.07 |
35 |
95.8 ± 28.9 |
0.38 |
0.85 |
| 3 M |
98.9 ± 35.6 |
98.0 ± 28.1 |
|
|||||
| 6 M |
95.4 ± 32.4 |
91.8 ± 25.1 |
||||||
| 12 M |
100.0 ± 33.1 |
94.3 ± 27.2 |
0.39 |
|||||
| Total cholesterol mg/dl |
0 |
66 |
164.8 ± 37.1 |
0.27 |
35 |
163.5 ± 33.4 |
0.18 |
0.86 |
| 3 M |
167.7 ± 40.7 |
171.7 ± 35.1 |
|
|||||
| 6 M |
163.4 ± 38.9 |
164.8 ± 38.0 |
||||||
| 12 M |
167.3 ± 43.5 |
165.1 ± 35.8 |
0.79 |
|||||
| HDL mg/dl |
0 |
66 |
33.1 ± 9.5* |
<0.001 |
35 |
36.6 ± 10.7 |
0.18 |
0.10 |
| 3 M |
37.2 ± 11.3 |
37.0 ± 11.7 |
|
|||||
| 6 M |
36.6 ± 10.9 |
37.3 ± 12.9 |
||||||
| 12 M |
36.8 ± 10.8 |
34.3 ± 15.4 |
0.40 |
|||||
| HDL ≤40 mg/dl at study initiation |
0 |
54 |
29.7 ± 5.7* |
<0.001 |
23 |
30.2 ± 5.6 |
0.09 |
0.84 |
| 3 M |
33.8 ± 7.8 |
31.2 ± 7.6 |
|
|||||
| 6 M |
33.6 ± 7.7 |
31.8 ± 10.2 |
||||||
| 12 M |
33.6 ± 7.5 |
27.6 ± 11.6 |
0.03 |
|||||
| TG mg/dl |
0 |
66 |
183.6 ± 101.6** |
0.05 |
35 |
176.7 ± 86.7 |
0.04 |
0.73 |
| 3 M |
175.7 ± 90.8 |
192.9 ± 100.7 |
|
|||||
| 6 M |
174.0 ± 89.8 |
193.6 ± 90.5 |
||||||
| 12 M |
167.3 ± 86.3 |
206.1 ± 109.4 |
0.05 |
|||||
| TG ≥200 mg/dl at study initiation | 0 |
20 | 310.1 ± 87.8** |
0.02 | 10 | 288.1 ± 71.9 |
0.15 | 0.13 |
| 3 M |
267.3 ± 86.6 |
318.2 ± 96.6 |
|
|||||
| 6 M |
248.7 ± 100.5 |
301.5 ± 78.2 |
||||||
| 12 M | 237.4 ± 102.5 | 320.4 ± 56.8 | 0.008 | |||||
*P < 0.05 for zero time vs. 3, 6 and 12 m; **P < 0.05 for zero time vs. 6 m and 12 m; ***T-test or Mann-whitny U test.